Mycobacterium avium complex infection epidemiology and demographics

Mycobacterium avium complex infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Mycobacterium avium complex infection from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mycobacterium avium complex infection epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mycobacterium avium complex infection epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mycobacterium avium complex infection epidemiology and demographics
CDC on Mycobacterium avium complex infection epidemiology and demographics
Mycobacterium avium complex infection epidemiology and demographics in the news
Blogs on Mycobacterium avium complex infection epidemiology and demographics
Directions to Hospitals Treating Mycobacterium avium complex infection
Risk calculators and risk factors for Mycobacterium avium complex infection epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Epidemiology and Demographics

Not reportable. Population-based data available for Houston and Atlanta metropolitan areas suggest a rate of 1/100,000/year. Incidence is decreasing among HIV- infected patients as a result of new treatment modalities e.g., combination therapy with nucleoside reverse transcriptase inhibitors and protease inhibitors, as well as antimycobacterial prophylaxis. Incidence is decreasing because of changes in treatment for HIV-infected patients; however, antimicrobial resistance may be increasing.